Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018http://www.reportlinker.com/p0358211/Cervical-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary Scope- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cervical Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cervical Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cervical Cancer Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cervical Cancer Therapeutics market
Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Cervical Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cervical Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Cervical Cancer Therapeutics market landscape? – Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Cervical Cancer - Introduction 8
2.1 Introduction 8
2.2 Disease Definition 8
2.3 Cytology Classification Systems for Cervical Neoplasms 8
2.4 Epidemiology 9
2.5 Etiology and Pathophysiology 10
2.6 Risk Factors for Cervical Cancer 12
2.7 Symptoms 13
2.8 Diagnosis 13
2.8.1 Pap Smear 13
2.8.2 Colposcopy 13
2.8.3 Biopsy 14
2.8.4 Human Papillomavirus Test 14
2.8.5 Pelvic Exam 14
2.8.6 Endocervical Curettage 14
2.8.7 Other Methods of Detecting HPV Infections 14
2.9 Staging of Cervical Cancer 15
2.10 Treatment for Patients with Cervical Cancer 16
2.10.1 Surgery 16
2.10.2 Radiation Therapy 17
2.10.3 Chemotherapy 17
2.11 Treatment by Stage of the Disease 19
2.12 Cervical Cancer Screening Guidelines in the US 21
2.13 GlobalData Pipeline Report Guidance 24
3 Cervical Cancer - Market Characterization 25
3.1 Cervical Cancer Market Size (2005-2010) - Global 25
3.2 Cervical Cancer Market Forecast (2010-2018) – Global 28
3.3 Cervical Cancer Market Size (2005-2010) - The US 31
3.4 Cervical Cancer Market Forecast (2010-2018) - The US 34
3.5 Cervical Cancer Market Size (2005-2010) - The UK 37
3.6 Cervical Cancer Market Forecast (2010-2018) - The UK 40
3.7 Cervical Cancer Market Size (2005-2010) - Germany 43
3.8 Cervical Cancer Market Forecast (2010-2018) - Germany 46
3.9 Cervical Cancer Market Size (2005-2010) - France 49
3.10 Cervical Cancer Market Forecast (2010-2018) - France 52
3.11 Cervical Cancer Market Size (2005-2010) - Italy 55
3.12 Cervical Cancer Market Forecast (2010-2018) - Italy 58
3.13 Cervical Cancer Market Size (2005-2010) - Spain 61
3.14 Cervical Cancer Market Forecast (2010-2018) - Spain 64
3.15 Cervical Cancer Market Size (2005-2010) - Japan 67
3.16 Cervical Cancer Market Forecast (2010-2018) - Japan 69
3.17 Drivers and Barriers for the Cervical Cancer Market 71
3.17.1 Drivers for the Cervical Cancer Market 71
3.17.2 Barriers for the Cervical Cancer Market 72
3.18 Opportunity and Unmet Need 74
3.18.1 Opportunity and Unmet Need for the Cervical Cancer Prophylactics Market 74
3.18.2 Opportunity and Unmet Need for the Cervical Cancer Therapeutics Market 75
3.19 Key Takeaway 76
4 Cervical Cancer Market - Competitive Assessment 77
4.1 Overview 77
4.2 Strategic Competitor Assessment 77
4.2.1 Limitations of Current HPV Vaccines 78
4.2.2 Reimbursement Policy in The US 79
4.2.3 Competitor Assessment within Different Categories Employed in Cervical Cancer Treatment 80
4.3 Product Profile for Marketed Drugs and Vaccines in the Cervical Cancer Market 81
4.3.1 Gardasil (HPV quadrivalent (type 6, 11, 16 and 18) vaccine recombinant) 81
4.3.2 Cervarix (human papillomavirus bivalent (types 16 and 18)) 83
4.3.3 Hycamtin (topotecan hydrochloride) 84
4.4 Key Takeaway 86
5 Cervical Cancer - Pipeline Assessment 87
5.1 Overview 87
5.2 Strategic Pipeline Assessment 87
5.3 Cervical Cancer – Pipeline by Phases of Development 88
5.3.1 Cervical Cancer – Phase III Pipeline 89
5.3.2 Cervical Cancer – Phase II Pipeline 90
5.3.3 Cervical Cancer – Phase I/II Pipeline 91
5.3.4 Cervical Cancer – Phase I Pipeline 91
5.3.5 Cervical Cancer – Preclinical Pipeline 92
5.3.6 Cervical Cancer – Discovery Pipeline 92
5.4 Cervical Cancer– Pipeline by Mechanism of Action 93
5.5 Cervical Cancer – Pipeline by Treatment Approach 95
5.5.1 Technology Trends Analytic Framework 96
5.6 Cervical Cancer – Promising Drugs under Clinical Development 97
5.7 Molecule Profile for Promising Drugs under Clinical Development 97
5.7.1 V503 97
5.7.2 S-1 (in combination with cisplatin) 98
5.7.3 Z-100 (with radiation) 98
5.8 Challenges in the Development of Cervical Cancer Vaccines 99
5.8.1 Deficit of Animal Models for HPV 99
5.8.2 Poor Understanding of Immune Response to HPV 99
5.8.3 Effective Prevention can be Achieve with a Multivalent Vaccine 99
5.8.4 Limited Knowledge of the Mucosal Immune Response 99
5.9 Key Takeaway 99
6 Cervical Cancer - Clinical Trials Mapping 100
6.1 Clinical Trials by Country (US, EU5 and Japan) 100
6.2 Clinical Trials by Phase 101
6.3 Clinical Trials by Status 102
6.4 Overall Sponsors 103
6.5 Prominent Sponsors 104
6.6 Top Companies Participating in Cervical Cancer Clinical Trials 105
7 Cervical Cancer - Strategic Assessment 106
7.1 Cervical Cancer Therapeutics: Implications for Future Market Competition 106
8 Cervical Cancer - Future Players 108
8.1 Introduction 108
8.2 Company Profiles 108
8.2.1 Merck & Co., Inc. (Merck). 108
8.2.2 Sanofi Pasteur MSD (Subsidiary of Merck & Co., Inc.) 110
8.2.3 GlaxoSmithKline plc (GSK) 110
8.2.4 Zeria Pharmceutical Co., Ltd. (Zeria) 112
8.2.5 Taiho Pharmaceutical Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd.) 113
8.2.6 Other Companies in the Cervical Cancer Market 114
9 Cervical Cancer: Licensing and Partnership Deals 118
10 Cervical Cancer Therapeutics - Appendix 122
10.1 Market Definitions 122
10.2 Abbreviations 122
10.3 Methodology 123
10.3.1 Coverage 123
10.3.2 Secondary Research 124
10.3.3 Forecasting 124
10.3.4 Primary Research 126
10.3.5 Expert Panel Validation 127
10.4 Contact Us 127
10.5 Disclaimer 127
10.6 Bibliography 127
List of Tables
Table 1: Cervical Cancer, Incidence and Mortality Cases in 2010 10
Table 2: Cervical Cancer Staging – TNM and FIGO, 2011 16
Table 3: Comparison of Cervarix and Gardasil 18
Table 4: Cervical Cancer Screening Guidelines in the US 21
Table 5: Recommendations# and Funding Status for HPV Vaccines in EU5 as of November 01, 2007 22
Table 6: Cervical Cancer Market, Global, Revenue ($m), 2005–2010 27
Table 7: Cervical Cancer Market, Global, Forecast ($m), 2010–2018 30
Table 8: Cervical Cancer Market, The US, Revenue ($m), 2005–2010 33
Table 9: Cervical Cancer Market, The US, Forecast ($m), 2010–2018 36
Table 10: Cervical Cancer Market, The UK, Revenue ($m), 2005–2010 39
Table 11: Cervical Cancer Market, The UK, Forecast ($m), 2010–2018 42
Table 12: Cervical Cancer Market, Germany, Revenue ($m), 2005–2010 45
Table 13: Cervical Cancer Market, Germany, Forecast ($m), 2010–2018 48
Table 14: Cervical Cancer Market, France, Revenue ($m), 2005–2010 51
Table 15: Cervical Cancer Market, France, Forecast ($m), 2010–2018 54
Table 16: Cervical Cancer Market, Italy, Revenue ($m), 2005–2010 57
Table 17: Cervical Cancer Market, Italy, Forecast ($m), 2010–2018 60
Table 18: Cervical Cancer Market, Spain, Revenue ($m), 2005–2010 63
Table 19: Cervical Cancer Market, Spain, Forecast ($m), 2010–2018 66
Table 20: Cervical Cancer Market, Japan, Revenue ($m), 2005–2010 68
Table 21: Cervical Cancer Market, Japan, Forecast ($m), 2010–2018 71
Table 22: Description of Prophylactic Cervical Cancer Vaccines 78
Table 23: Gardasil Approvals and Fillings 82
Table 24: Major Marketed Drugs and Vaccines Comparison in the Cervical Cancer Market, 2011 85
Table 25: Cervical Cancer – Phase III Pipeline, 2011 89
Table 26: Cervical Cancer – Phase II Pipeline, 2011 90
Table 27: Cervical Cancer – Phase I/II Pipeline, 2011 91
Table 28: Cervical Cancer – Phase I Pipeline, 2011 91
Table 29: Cervical Cancer – Preclinical Pipeline, 2011 92
Table 30: Cervical Cancer – Discovery Pipeline, 2011 92
Table 31: Mechanism of Action for the 'Other' Molecules in Figure 68 94
Table 32: Cervical Cancer– Promising Drugs Under Clinical Development, 2011 97
Table 33: Cervical Cancer – Clinical Trials by Country, 2011 100
Table 34: Cervical Cancer – Clinical Trials by Phase, 2011 101
Table 35: Cervical Cancer – Clinical Trials by Status, 2011 102
Table 36: Cervical Cancer – Overall Sponsors, 2011 103
Table 37: Cervical Cancer – Prominent Sponsors, 2011 104
Table 38: Cervical Cancer: Top Companies Participating in Clinical Trials, 2011 105
Table 39: Cervical Cancer Market – Other Future Players, 2011 114
Table 40: Cervical Cancer, Licensing and Partnership Deals, 2011 118
List of Figures
Figure 1: Comparison of Cytology Classification Systems for Cervical Neoplasms 8
Figure 2: Cervical Cancer, Incidence and Mortality Cases in 2010 9
Figure 3: Human Papillomavirus Infection and Replication in Cervical Epithelial Cells 10
Figure 4: Clinical Pathology of Cervical Cancer 12
Figure 5: Pap Smear Test 13
Figure 6: Pelvic Exam 14
Figure 7: Stages of Cervical Cancer 15
Figure 8: Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer 17
Figure 9: Cervical Cancer Treatment by Stage of Disease, 2011 19
Figure 10: Cervical Cancer Treatment and Dosage - Chemo-radiation Therapy or Chemotherapy by Stage, 2011 20
Figure 11: Cervical Cancer Prophylactics Market, Global, Revenue ($m), 2006-2010 25
Figure 12: Cervical Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010 26
Figure 13: Cervical Cancer, Global, Market Share (%), 2010 26
Figure 14: Cervical Cancer Prophylactics Market, Global, Forecasts ($m), 2010-2018 28
Figure 15: Cervical Cancer Therapeutics Market, Global, Forecasts ($m), 2010-2018 29
Figure 16: Cervical Cancer, Global, Market Share (%), 2018 29
Figure 17: Cervical Cancer Prophylactics Market, The US, Revenue ($m), 2006-2010 31
Figure 18: Cervical Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010 32
Figure 19: Cervical Cancer, The US, Market Share (%), 2010 32
Figure 20: Cervical Cancer Prophylactics Market, The US, Forecasts ($m), 2010-2018 34
Figure 21: Cervical Cancer Therapeutics Market, The US, Forecasts ($m), 2010-2018 35
Figure 22: Cervical Cancer, The US, Market Share (%), 2018 35
Figure 23: Cervical Cancer Prophylactics Market, The UK, Revenue ($m), 2007-2010 37
Figure 24: Cervical Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010 38
Figure 25: Cervical Cancer, The UK, Market Share (%), 2010 38
Figure 26: Cervical Cancer Prophylactics Market, The UK, Forecast ($m), 2010-2018 40
Figure 27: Cervical Cancer Therapeutics Market, The UK, Forecast ($m), 2010-2018 41
Figure 28: Cervical Cancer, The UK, Market Share (%), 2018 41
Figure 29: Cervical Cancer Prophylactics Market, Germany, Revenue ($m), 2007-2010 43
Figure 30: Cervical Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 44
Figure 31: Cervical Cancer, Germany, Market Share (%), 2010 44
Figure 32: Cervical Cancer Prophylactics Market, Germany, Forecast ($m), 2010-2018 46
Figure 33: Cervical Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018 47
Figure 34: Cervical Cancer, Germany, Market Share (%), 2018 47
Figure 35: Cervical Cancer Prophylactics Market, France, Revenue ($m), 2007-2010 49
Figure 36: Cervical Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 50
Figure 37: Cervical Cancer, France, Market Share (%), 2010 50
Figure 38: Cervical Cancer Prophylactics Market, France, Forecast ($m), 2010-2018 52
Figure 39: Cervical Cancer Therapeutics Market, France, Forecast ($m), 2010-2018 53
Figure 40: Cervical Cancer, France, Market Share (%), 2018 53
Figure 41: Cervical Cancer Prophylactics Market, Italy, Revenue ($m), 2007-2010 55
Figure 42: Cervical Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 56
Figure 43: Cervical Cancer, Italy, Market Share (%), 2010 56
Figure 44: Cervical Cancer Prophylactics Market, Italy, Forecast ($m), 2010-2018 58
Figure 45: Cervical Cancer Prophylactics Market, Italy, Forecast ($m), 2010-2018 59
Figure 46: Cervical Cancer, Italy, Market Share (%), 2018 59
Figure 47: Cervical Cancer Prophylactics Market, Spain, Revenue ($m), 2007-2010 61
Figure 48: Cervical Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 62
Figure 49: Cervical Cancer, Spain, Market Share (%), 2010 62
Figure 50: Cervical Cancer Prophylactics Market, Spain, Forecast ($m), 2010-2018 64
Figure 51: Cervical Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018 65
Figure 52: Cervical Cancer, Spain, Market Share (%), 2018 65
Figure 53: Cervical Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 67
Figure 54: Cervical Cancer, Japan, Market Share (%), 2010 68
Figure 55: Cervical Cancer Prophylactics Market, Japan, Forecast ($m), 2010-2018 69
Figure 56: Cervical Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018 70
Figure 57: Cervical Cancer, Japan, Market Share (%), 2018 70
Figure 58: Cervical Cancer Market, Drivers and Barriers, 2011 72
Figure 59: Cervical Cancer Market, Drivers and Barriers and its Influence, 2011 73
Figure 60: Opportunity and Unmet Need for Cervical Cancer Prophylactics Market, 2011 74
Figure 61: Opportunity and Unmet Need for Cervical Cancer Therapeutics Market, 2011 75
Figure 62: Implementation and Financing Policy in The US 79
Figure 63: Cervical Cancer Prophylactics Market – Strategic Competitor Assessment, 2011 80
Figure 64: Cervical Cancer Therapeutics Market – Strategic Competitor Assessment, 2011 81
Figure 65: Cervical Cancer – Pipeline by Phase of Development, 2011 88
Figure 66: Cervical Cancer – Clinical Pipeline by Mechanism of Action, 2011 93
Figure 67: Overall Cervical Cancer – Clinical Pipeline by Treatment Type, 2011 95
Figure 68: Cervical Cancer – Clinical Pipeline Comparing Treatment Types, 2011 95
Figure 69: Cervical Cancer – Technology Trends Analytics Framework, 2011 96
Figure 70: Cervical Cancer – Clinical Trials by Country, 2011 100
Figure 71: Cervical Cancer – Clinical Trials by Phase, 2011 101
Figure 72: Cervical Cancer – Clinical Trials by Status, 2011 102
Figure 73: Cervical Cancer – Overall Sponsors, 2011 103
Figure 74: Cervical Cancer – Prominent Sponsors, 2011 104
Figure 75: Cervical Cancer – Prominent Sponsors, 2011 105
Figure 76: Implications for Future Market Competition in Cervical Cancer Prophylactics Market, 2011 106
Figure 77: Implications for Future Market Competition in Cervical Cancer Therapeutics Market, 2011 107
Figure 78: GlobalData Market Forecasting Model 126
Companies mentioned
Merck & Co., Inc. (Merck).
Sanofi Pasteur MSD (Subsidiary of Merck & Co., Inc.)
GlaxoSmithKline plc (GSK)
Zeria Pharmceutical Co., Ltd. (Zeria)
Taiho Pharmaceutical Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd.)
To order this report:Pathology Industry: Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
More
Market Research ReportCheck our
Industry Analysis and InsightsNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article